Nicotinamide Riboside ( DrugBank: Nicotinamide, Nicotinamide riboside )

5 diseases

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04562831 (ClinicalTrials.gov)	October 7, 2020	10/9/2020	The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.	A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study	Amyotrophic Lateral Sclerosis	Dietary Supplement: EH301 (Nicotinamide Riboside/Pterostilbene)	Haukeland University Hospital	Elysium Health	Recruiting	35 Years	N/A	All	380	N/A	Norway

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05589766 (ClinicalTrials.gov)	November 28, 2022	13/10/2022	N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease	N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease	Parkinson Disease	Dietary Supplement: Nicotinamide Riboside;Other: Placebo	Haukeland University Hospital	NULL	Recruiting	40 Months	100 Years	All	80	N/A	Norway
2	NCT03568968 (ClinicalTrials.gov)	May 15, 2020	14/6/2018	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study	Parkinson Disease	Dietary Supplement: Nicotinamide Riboside;Drug: Placebo	Haukeland University Hospital	NULL	Recruiting	18 Years	N/A	All	400	N/A	Norway
3	NCT03816020 (ClinicalTrials.gov)	March 9, 2019	7/12/2018	NAD-supplementation in Drug naïve Parkinson's Disease	NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease	Parkinson Disease;Neurodegenerative Diseases	Dietary Supplement: Nicotinamide Riboside;Other: Placebo	Haukeland University Hospital	NULL	Completed	18 Years	N/A	All	30	N/A	Norway

臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04192136 (ClinicalTrials.gov)	September 3, 2020	6/12/2019	NAD+ and Exercise in FA	NAD+ Precursor Supplementation With Exercise Training to Increase Aerobic Capacity in Friedreich's Ataxia	Friedreich Ataxia 1	Dietary Supplement: Nicotinamide Riboside;Dietary Supplement: Placebo;Other: Exercise Intervention	Children's Hospital of Philadelphia	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	10 Years	40 Years	All	72	N/A	United States

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05561738 (ClinicalTrials.gov)	January 1, 2023	13/9/2022	Nicotinamide Riboside in Ulcerative Colitis	Nicotinamide Riboside in Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Nicotinamide Riboside Chloride;Dietary Supplement: Placebo;Other: Standard of Care	University of Pittsburgh	Crohn's and Colitis Foundation	Not yet recruiting	N/A	18 Years	All	40	N/A	United States

臨床試験数 : 3 / 薬物数 : 4 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031190141	19/03/2021	27/11/2019	Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome	Prospective, single-center, cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome - EMPOWER	Werner syndrome Werner syndrome;C16.320.925 / C18.452.284.960	Subjects ingest oral capsules of NR (nicotinamide riboside) once daily (total daily dose: nicotinamide riboside 1000 mg).	Yokote Koutaro	NULL	Recruiting	>= 20age old	Not applicable	Both	30	Phase 1-2	Japan